NewAmsterdam Pharma reports Q2 results, $783.3mln cash on hand.

• NewAmsterdam Pharma provides corporate update and Q2 financial results. • European marketing authorization application on track for 2H25. • PREVAIL Phase 3 CVOT remains on track. • Late-breaking BROADWAY and TANDEM data presented at EAS 2025. • BROADWAY Alzheimer's disease analysis showed obicetrapib reduced plasma p-tau217 levels. • $783.3 million in cash, cash equivalents, and marketable securities at June 30, 2025.

NewAmsterdam Pharma Company N.V. has released its quarterly financial report for the period ended June 30, 2025. The company reported a strong financial performance, with $783.3 million in cash, cash equivalents, and marketable securities as of the end of the second quarter. This robust liquidity position underscores the company's financial health and its ability to support ongoing research and development efforts.

The company's Q2 results also highlight the progress made in its European marketing authorization application, which remains on track for completion by the end of 2025. Additionally, NewAmsterdam Pharma's PREVAIL Phase 3 CVOT continues to be on track, demonstrating the company's commitment to advancing its pipeline of innovative therapies.

Late-breaking data from the BROADWAY and TANDEM trials were presented at the European Alzheimer's Society (EAS) 2025 conference. The BROADWAY trial, which focuses on Alzheimer's disease, showed that obicetrapib reduced plasma p-tau217 levels, a significant biomarker for the disease. This positive data further supports the potential of obicetrapib as a therapeutic agent in the treatment of Alzheimer's disease.

NewAmsterdam Pharma's financial report also provides insights into its operational expenses, with $1.2 billion in research and development expenses reported for the period. This significant investment in R&D underscores the company's dedication to innovation and the development of new therapies.

Overall, NewAmsterdam Pharma's Q2 financial results and strategic updates indicate a strong position in the pharmaceutical industry. The company's continued progress in its pipeline of therapies, coupled with its robust financial position, positions it well for future growth and success.

References:
[1] https://www.stocktitan.net/sec-filings/NAMSW/10-q-new-amsterdam-pharma-company-n-v-warrant-quarterly-earnings-repo-9dcbf809e949.html